Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy

Inclusion Criteria:

* The patient has cytologically proven AML as defined by the World Health Organization (WHO) classification. The pretreatment AML karyotype should be documented.
* The leukemia is a de novo or secondary AML.
* The patient's blasts cells show expression of WT1 transcript, detected by quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR).The patient received the following therapy according to the Institution's standard of care.

  * For patients \< 60 years old: at least two induction chemotherapy treatments.
  * For patients \>= 60 years old: at least one induction chemotherapy treatment or alternative treatment.
* The first ASCI administration should be given within one year after the last chemotherapy administration. All screening procedures should be completed within seven weeks before the first ASCI administration.
* In the investigator's opinion and in compliance with the Institution Hematology Tumor Board's guidances, the patient should not be eligible for any additional chemotherapy treatment before the ASCI treatment.
* The clinical status of the patient at inclusion is one of the following:

  * Partial Remission (PR)
  * Morphologic complete remission with incomplete blood count recovery (CRi)
* Written informed consent has been obtained prior to the performance of any protocol-specific procedure.
* The patient is \>= 18 years of age at the time of signature of the first informed consent form.
* Eastern Cooperative Oncology Group performance status of 0, 1 or 2.
* Adequate hepatic and renal function defined as:

  * Serum bilirubin \< 1.5 times the Upper Limit of Nor-mal (ULN).
  * Serum ALT \< 2.5 times the ULN.
  * Calculated creatinine clearance \> 50 mL/min.
* In the view of the investigator, the patient can and will comply with the requirements of the protocol.
* If the patient is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal, or if she is of childbearing potential, then she must practice adequate contraception for 30 days prior to treatment administration, have a negative pregnancy test and continue such precautions for 2 months after completion of the treatment administration series.

Exclusion Criteria:

* The patient was diagnosed with leukemic Central Nervous System (CNS) disease (e.g. before chemotherapy) or presents neurological symptoms at baseline suggestive of a CNS involvement.
* The patient has acute promyelocytic leukemia with t(15;17) (q22;q12), (PML/RARα) or variants.
* The patient has received, or is receiving, allogeneic Stem Cell Transplantation (SCT).
* The patient has received Fludarabine, Clofarabine or Cloretazine within 12 months preceding the ASCI treat-ment.
* The patient has hypercalcemia.
* The patient is known to be HIV-positive.
* The patient has symptomatic autoimmune disease such as, but not limited to multiple sclerosis, lupus, and in-flammatory bowel disease. Patients with vitiligo are not excluded.
* The patient has a history of allergic reactions likely to be exacerbated by any component of the study investigational product.
* The patient has other concurrent severe medical prob-lems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.
* The patient has another metastatic cancer disease.
* The patient has a history of congestive heart failure, coronary artery disease or previous myocardial infarction.
* The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the study procedures.
* The patient has received any investigational or non-registered medicinal product other than the study treat-ment within 30 days preceding the first dose of study treatment or plans to receive such a drug during the study period.
* The patient requires concomitant chronic treatment (more than 7 consecutive days) with systemic corticosteroids or any other immunosuppressive agents.
* The patient is receiving full dose subcutaneous heparins or is under anti-coagulation treatment.
* For female patients: the patient is pregnant or lactating.